Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pracinostat - MEI Pharma

Next Previous
X
Search
Drug Profile

Pracinostat - MEI Pharma

Alternative Names: SB-939

Latest Information Update: 01 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator S*BIO
  • Developer Helsinn; MEI Pharma; S*BIO; University of Texas M. D. Anderson Cancer Center
  • Class Acrylamides; Amines; Antineoplastics; Hydroxamic acids; Imidazoles; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Myelodysplastic syndromes; Myelofibrosis

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 25 Mar 2022 Helsinn terminates the phase II trial for Myelodysplastic syndromes (Combination therapy) in USA (NCT03151304)
  • 19 Nov 2021 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top